BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 31229162)

  • 41. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
    Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
    Int J Hematol; 2017 Sep; 106(3):426-430. PubMed ID: 28466385
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
    Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
    Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted therapies for cutaneous T-cell lymphomas.
    Kaplan JB; Guitart J; Giles FJ
    Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.
    Horwitz SM; Olsen EA; Duvic M; Porcu P; Kim YH
    J Natl Compr Canc Netw; 2008 Apr; 6(4):436-42. PubMed ID: 18433609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mycosis fungoides and the Sézary syndrome.
    Gisselbrecht C; Dubertret L
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):73-5. PubMed ID: 8511044
    [No Abstract]   [Full Text] [Related]  

  • 46. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.
    Whittaker SJ; Marsden JR; Spittle M; Russell Jones R; ;
    Br J Dermatol; 2003 Dec; 149(6):1095-1107. PubMed ID: 14696593
    [No Abstract]   [Full Text] [Related]  

  • 47. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; Wilcox RA
    Am J Hematol; 2023 Jan; 98(1):193-209. PubMed ID: 36226409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of hematopoietic stem-cell transplantation in cutaneous T-cell lymphoma.
    Hoff NP; Bruch-Gerharz D
    G Ital Dermatol Venereol; 2010 Jun; 145(3):345-59. PubMed ID: 20461043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of cutaneous T-cell lymphomas: Established and emergent therapies.
    Wain T; Venning VL; Consuegra G; Fernandez-Peñas P; Wells J
    Australas J Dermatol; 2019 Aug; 60(3):200-208. PubMed ID: 30809800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.
    Laharanne E; Oumouhou N; Bonnet F; Carlotti M; Gentil C; Chevret E; Jouary T; Longy M; Vergier B; Beylot-Barry M; Merlio JP
    J Invest Dermatol; 2010 Jun; 130(6):1707-18. PubMed ID: 20130593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
    Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary Cutaneous Lymphomas in Children and Adolescents.
    Ceppi F; Pope E; Ngan B; Abla O
    Pediatr Blood Cancer; 2016 Nov; 63(11):1886-94. PubMed ID: 27229270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myocosis fungoides--an update on a non-mycotic disease.
    Makdisi J; Friedman A
    J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Rare variants of cutaneous T-cell lymphomas].
    Goerdt S; Trautmann C; Kütting B; Ramaker J; Schmuth M; Thiel E; Luger T; Stein H; Orfanos CE
    Hautarzt; 1996 Feb; 47(2):96-105. PubMed ID: 8868452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Mycosis fungoides and Sézary syndrome, so-called cutaneous T-cell lymphoma].
    Rupniewska ZM
    Postepy Hig Med Dosw; 1982; 36(4):231-49. PubMed ID: 6764803
    [No Abstract]   [Full Text] [Related]  

  • 58. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
    Parker SR; Bethaney JV
    G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).
    Bunn PA; Hoffman SJ; Norris D; Golitz LE; Aeling JL
    Ann Intern Med; 1994 Oct; 121(8):592-602. PubMed ID: 8085692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].
    Albrecht JD; Nicolay JP
    Hautarzt; 2022 Jan; 73(1):75-85. PubMed ID: 34988613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.